History
For over 30 years our companies have made treating complex and life-threatening conditions possible, supporting clinicians, healthcare systems and governments while offering hope to patients and their families.
-
October 2024
Acquired Aurlumyn™ (iloprost IV) from CiVi Biopharma
-
July 2024
Acquired RSDL® (Reactive Skin Decontamination Lotion) from Emergent BioSolutions Inc.
-
July 2023
Acquired Vistogard and Xuriden
-
April 2022
Acquired the rights to Xermelo outside the US and Japan from Ipsen.
-
January 2022
Voraxaze approved in Europe.
-
March 2021
SERB acquires BTG Specialty Pharmaceuticals, adding a US commercial presence, bio-manufacturing and R&D capabilities, and products including DIGIFab, Voraxaze, and CroFab.
-
2020
Licensed Ammonul from Bausch & Lomb.
-
2020
Acquired Effortil from Sanofi SA.
-
March 2020
SERB acquires Veriton Pharma, adding a direct commercial presence in the UK, the Middle East and Australia, and adding rare disease products such as Epistatus.
-
2019
BTG plc acquired by Boston Scientific – BTG Specialty Pharmaceutical re-organises as a self-sufficient business.
-
2019
Licensed Firdapse from Biomarin (Europe).
-
2018
SERB acquires critical care business of EUSA Pharma, including EUSA’s field-based critical care sales teams and products including Fomepizole, Collatamp, Custodiol (critical care), Xenazine.
-
2018
Thyrosafe/Kaliumjodid acquired from Recipharm.
-
2017
Toxogonin acquired from Merck.
-
October 2017
Special Products Limited changed its company name to Veriton Pharma.
-
September 2017
Epistatus is licensed in the UK
-
2017
Charterhouse Capital Partners, a London-based private equity firm, acquires a majority stake in SERB and dedicates significant financial and human resources to the company’s development.
-
2015
Cyanokit® acquired from Merck.
-
2013
Licensed Radiogardase from Heyl Pharmaceuticals.
-
2012
Voraxaze® (glucarpidase) approved and launched in the US.
-
2010
DIGIFab® (digoxin immune Fab (ovine)) receives first European regulatory approval
-
2010
BTG begins directly selling its own products in the US.
-
2008
BTG Plc acquired Protherics plc, a developer of new immunotherapeutic products and therapies.
-
2002
DIGIFab® (digoxin immune Fab (ovine)) launched in the US.
-
2001
CroFab® (crotalidae polyvalent immune fab (ovine)) launched in the US.
-
1997
Special Products Ltd (later Veriton Pharma) founded by Dr Graham March, a pharmacist with experience working at Great Ormond Street Hospital, and at major pharmaceutical companies. The company focused on unlicensed medicines for patients with special requirements.
-
1981
BTG (British Technology Group) is formed by the British government from the merger of the National Research & Development Council and the National Enterprise Board. The group is later privatised (1992) and listed on the London Stock exchange (1995).
-
1951
SERB (Société d’Études et de Recherches Biologiques) is created in Paris.
